We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters to the Editor |

Marked Reduction of Tardive Dyskinesia With Olanzapine

Kimberly H. Littrell, APRN; Craig G. Johnson, MD; Steven Littrell, MA; Carol D. Peabody
Arch Gen Psychiatry. 1998;55(3):279-280. doi:.
Text Size: A A A
Published online


Tardive dyskinesia (TD) is a syndrome of involuntary hyperkinetic abnormal movements that can occur in predisposed individuals during or shortly after the cessation of long-term antipsychotic drug therapy.1 The focus of clinical work with long-term antipsychotic therapy has been to optimize the benefit-to-risk ratio of adverse events, especially TD. The risk of developing TD is believed to increase with total cumulative drug exposure. This risk, on average, is about 5% per treatment year for the first 5 to 7 years,2 decreasing slightly thereafter but reaching a staggering 68% by 20 years.3 The introduction of atypical antipsychotic medications in this decade has demonstrated therapeutic effects for patients with preexisting TD.46 Olanzapine, a new atypical antipsychotic, has recently become available in the United States. It is characterized as a selective monoaminergic antagonist with high-affinity binding to serotonin, dopamine, muscarinic, histamine, and adrenergic receptors.7 The actual risk of TD with olanzapine was examined in the extension phase of study.4 Preliminary results show a significantly lower incidence (one-third to one-fourth lower) of new TD among those patients receiving olanzapine than in those receiving the typical antipsychotic medication, haloperidol decanoate.8


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

50 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.